ada guidelines glp 1 Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists The New ADA/EASD Type 1

Encourage fat loss around the midsection

Pre-clinical studies in genetically modified animal model of T2DM (OLETF rats, Otsuka Long Evans Tokushima fatty rats) have shown high PRA (plasmatic renin activity) levels, without any change in aldosterone levels under dapagliflozin chronic treatment, in accordance with the aforementioned observations of an independent intrarenal RAS (44)

they also suppress platelet activity, which may further contribute to cardiovascular protection ( 3.4 Complications and side effects of GLP-1 RAs Common side effects associated with GLP-1 receptor agonists (GLP-1 RAs) include gastrointestinal symptoms such as nausea (2560%), diarrhea, and vomiting (515%) ( While some studies have suggested a possible association between GLP-1 RAs and acute kidney injury (AKI), this has not been confirmed and appears to occur primarily in patients with underlying risk factors such as dehydration or severe gastrointestinal symptoms ( GLP-1 RA therapy should be discontinued under specific clinical conditions to minimize risk

By including it in a metabolic program, providers aim to support the bodys largest organ from the inside out